Abstract
Importance of the field: Microfluidic electrophoretic mobility shift assays are becoming increasingly popular with screening groups throughout the pharmaceutical industry due to their excellent data quality and target flexibility.Areas covered in this review: This review summarizes our experience of the microfluidic electrophoretic mobility shift technique at Merck Serono as well as from the published literature. We assess the advantages and limitations of electrophoretic mobility shift assays in this context.What the reader will gain: Published literature on the topic is scarce. The reader will gain an insight into the techniques and issues with the use of this technology in a pharmaceutical setting.Take home message: This technology has reached maturity, providing reliable and robust results. Current limitations are the lower-than-desired throughput capacity for primary screening campaigns, and its current restriction to enzyme classes catalyzing a significant change in mass/charge of the substrate.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
